InterMune ITMN
-
InterMune ([[ ITMN ]] -1.4%) sells its Actimmune interferon gamma-1b business to privately held Vidara Therapeutics International for $55M in cash plus a two-year royalty stream. The company had ...
InterMune ( ITMN -1.4% ) sells its Actimmune interferon gamma-1b business to privately held Vidara Therapeutics International for $55M in …
-
InterMune is in the Process of Launching Esbriet Abroad; We Expect Sales to Ramp Throughout 2012
InterMune 's ITMN first-quarter results showed slow ..... in Europe are causing large swings in InterMune 's stock, we think the overall outlook ..... point to own this orphan drugmaker. InterMune reported product revenue of $8.9 …
-
New Morningstar Analyst Report - InterMune , Inc.
… approval in Europe in 2011. InterMune has sold its rights to protease inhibitor ITMN -191 to Roche for ..... Esbriet's basket, InterMune has decided to sell its ..... inhibitor danoprevir ( ITMN -191), to partner ..... divestment will save InterMune roughly $50 million …
-
Top Small-Cap Biotech Stocks Being Accumulated By Legendary Fund Managers
By Ganaxi Small Cap Movers : The biotech group as represented by the NYSE ARCA Biotech Index ($BTK) has been strong this year, now up over 21% YTD. With both the market and the biotech sector in strong bull mode, now maybe an opportune time to go 'shop' for biotech stocks. In this article, via an
-
Spectrum Will Surge Higher On FOTOLYN Approval
By Stock Croc : There's been some important news regarding Spectrum Pharmaceuticals ( SPPI ) and it has not been good. The news concerns the bladder cancer drug, apaziquone, a hopeful product that company trumpeted, has failed in two separate phase two trials . And, although this is seen as a major
-
Intermune's Long Slog With Esbriet Shows No Sign Of Quickening
By EP Vantage : Intermune 's ( ITMN ) long slog with Esbriet continues ..... austerity measures across Europe mean Intermune is trying to launch its expensive ..... of Esbriet - the 75% collapse in Intermune 's share price over the last 12 …
-
Brean Murray is cutting its price target to $37 from $42 on InterMune ([[ ITMN ]] -1%) to reflect a more conservative outlook than the guidance management provided. The firm cites the potential denial ...
Brean Murray is cutting its price target to $37 from $42 on InterMune ( ITMN -1% ) to reflect a more conservative outlook than the guidance management provided. The firm cites the potential denial of European …
-
Recent Volatility Does Not Affect Long-Term Prospects of InterMune
InterMune 's ITMN shares have fluctuated widely in recent ..... Efficiency in Health Care in December, InterMune reported in March that German authorities ..... s initial assessment). Last week, InterMune announced that the French National Authority …
-
InterMune ([[ ITMN ]] -16.4%) tumbles on news that a key clinical trial for its respiratory drug Esbriet has been delayed. Last week, ITMN said it didn't expect enrollment for the Phase 3 clinical ...
InterMune ( ITMN -16.4% ) tumbles on news that a key clinical trial for its respiratory drug Esbriet has been delayed . Last week, ITMN said it didn't expect enrollment for the Phase 3 clinical trial to be …
-
InterMune ([[ ITMN ]] +6.1%) rallies after Wells Fargo notes French regulators gave a favorable rating to the company's Esbriet lung disease drug. Wells believes the rating should allow InterMune to ...
InterMune ( ITMN +6.1% ) rallies after Wells Fargo notes French regulators gave a favorable rating to the company's Esbriet lung disease drug. Wells believes the rating should allow InterMune to "negotiate premium pricing" for Esbriet. ( previously ) Post your comment!